Atea Pharmaceuticals (AVIR)

• Market cap: $473M
• 1 day: -1.63%
• 5 days: 25.26%
• 1 month: 45.43%
• 3 months: 91.46%
• 6 months: 92.06%
• Year to date: 73.85%
• 1 year: 107.19%
• 5 years: -90.56%
• 10 years: -80.06%
• Sector: Healthcare
• Industry: Biotechnology

About: Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants, and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Employees: 56